Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1/CIP1/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-β-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis
- Author
- ZHILIANG WANG1 ; VAN TUYLE, G2 ; CONRAD, D3 ; FISHER, P. B4 ; DENT, P5 ; GRANT, S1 2 3 6
[1] Department of Medicine, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0230, United States
[2] Department of Biochemistry, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0230, United States
[3] Department of Microbiology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0230, United States
[4] Departments of Pathology and Urology, Columbia University College of Physicians and Surgeons, New York, New York 10032, United States
[5] Department of Radiation Oncology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0230, United States
[6] Department of Pharmacology, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia 23298-0230, United States - Source
Cancer research (Baltimore). 1999, Vol 59, Num 6, pp 1259-1267 ; ref : 56 ref
- CODEN
- CNREA8
- ISSN
- 0008-5472
- Scientific domain
- Medical oncology; Pharmacology drugs
- Publisher
- American Association for Cancer Research, Philadelphia, PA
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Aigu Anticancéreux Apoptose Cellule tumorale Chimiothérapie Cytarabine DNA antisens Expression génique Gène suppresseur tumeur Homme In vitro Leucémie promyélocytaire Lignée cellulaire établie Mitochondrie Mécanisme action Produit gène Pyrimidine nucléoside Gène WAF1 Lignée U937 Hémopathie maligne
- Keyword (en)
- Acute Antineoplastic agent Apoptosis Tumor cell Chemotherapy Cytarabine Antisense DNA Gene expression Tumor suppressor gene Human In vitro Promyelocytic leukemia Established cell line Mitochondria Mechanism of action Gene product Pyrimidine nucleoside Malignant hemopathy
- Keyword (es)
- Agudo Anticanceroso Apoptosis Célula tumoral Quimioterapia Citarabina DNA antisentido Expresión genética Gen supresor tumor Hombre In vitro Leucemia promielocítica Línea celular establecida Mitocondria Mecanismo acción Producto gene Pirimidina nucleósido Hemopatía maligna
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 1722206
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Install on your browser
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1259\";s:8:\"\u0000*\u0000epage\";s:4:\"1267\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"ZHILIANG WANG\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"VAN TUYLE, G\";i:1;s:9:\"CONRAD, D\";i:2;s:12:\"FISHER, P. B\";i:3;s:7:\"DENT, P\";i:4;s:8:\"GRANT, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1259\";s:8:\"\u0000*\u0000epage\";s:4:\"1267\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"ZHILIANG WANG\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"VAN TUYLE, G\";i:1;s:9:\"CONRAD, D\";i:2;s:12:\"FISHER, P. B\";i:3;s:7:\"DENT, P\";i:4;s:8:\"GRANT, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1259\";s:8:\"\u0000*\u0000epage\";s:4:\"1267\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"ZHILIANG WANG\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"VAN TUYLE, G\";i:1;s:9:\"CONRAD, D\";i:2;s:12:\"FISHER, P. B\";i:3;s:7:\"DENT, P\";i:4;s:8:\"GRANT, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1259\";s:8:\"\u0000*\u0000epage\";s:4:\"1267\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"ZHILIANG WANG\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"VAN TUYLE, G\";i:1;s:9:\"CONRAD, D\";i:2;s:12:\"FISHER, P. B\";i:3;s:7:\"DENT, P\";i:4;s:8:\"GRANT, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:0:\"\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:9:\"\u0000*\u0000jtitle\";s:27:\"Cancer research (Baltimore)\";s:9:\"\u0000*\u0000stitle\";s:23:\"Cancer res. (Baltimore)\";s:7:\"\u0000*\u0000date\";s:4:\"1999\";s:9:\"\u0000*\u0000volume\";s:2:\"59\";s:8:\"\u0000*\u0000issue\";s:1:\"6\";s:8:\"\u0000*\u0000spage\";s:4:\"1259\";s:8:\"\u0000*\u0000epage\";s:4:\"1267\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-5472\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:13:\"ZHILIANG WANG\";s:10:\"\u0000*\u0000aufirst\";s:0:\"\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:5:{i:0;s:12:\"VAN TUYLE, G\";i:1;s:9:\"CONRAD, D\";i:2;s:12:\"FISHER, P. B\";i:3;s:7:\"DENT, P\";i:4;s:8:\"GRANT, S\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CNREA8\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:216:\"Dysregulation of the cyclin-dependent kinase inhibitor p21WAF1\/CIP1\/MDA6 increases the susceptibility of human leukemia cells (U937) to 1-\u03b2-D-arabinofuranosylcytosine-mediated mitochondrial dysfunction and apoptosis\";s:8:\"\u0000*\u0000place\";s:16:\"Philadelphia, PA\";s:6:\"\u0000*\u0000pub\";s:40:\"American Association for Cancer Research\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
